Atypical Fibroxanthoma

Atypical fibroxanthoma (AFX) is a nodular dermal ulcerative lesion with a favorable prognosis. AFX most commonly occurs on sun-exposed skin in elderly individuals. AFX is characterized by its association with ultraviolet radiation, not only from a clinical aspect, but also from a molecular aspect. M...

Full description

Bibliographic Details
Main Author: Akio Sakamoto
Format: Article
Language:English
Published: SAGE Publishing 2008-01-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.4137/CMO.S506
id doaj-54be7482a25b463f825bb08c764ae072
record_format Article
spelling doaj-54be7482a25b463f825bb08c764ae0722020-11-25T03:48:09ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492008-01-01210.4137/CMO.S506Atypical FibroxanthomaAkio Sakamoto0Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.Atypical fibroxanthoma (AFX) is a nodular dermal ulcerative lesion with a favorable prognosis. AFX most commonly occurs on sun-exposed skin in elderly individuals. AFX is characterized by its association with ultraviolet radiation, not only from a clinical aspect, but also from a molecular aspect. Making a diagnosis of AFX is challenging, and it is important to differentiate it from squamous cell carcinoma and malignant melanoma. Histological features and combined immunohistochemical markers are necessary for a definitive diagnosis (i.e., an absence of immunostaining for cytokeratins, S100 and HMB45 in AFX is helpful for excluding both squamous cell carcinoma and malignant melanoma). AFX, as well as MFH (malignant fibrous histiocytoma), is a fibrohistiocytic lesion with myofibroblastic differentiation. AFX is considered to be a different lesion from MFH. AFX and MFH might share the same pathway which determines their morphology. However, they may have different pathways in development which determine their biological behavior.https://doi.org/10.4137/CMO.S506
collection DOAJ
language English
format Article
sources DOAJ
author Akio Sakamoto
spellingShingle Akio Sakamoto
Atypical Fibroxanthoma
Clinical Medicine Insights: Oncology
author_facet Akio Sakamoto
author_sort Akio Sakamoto
title Atypical Fibroxanthoma
title_short Atypical Fibroxanthoma
title_full Atypical Fibroxanthoma
title_fullStr Atypical Fibroxanthoma
title_full_unstemmed Atypical Fibroxanthoma
title_sort atypical fibroxanthoma
publisher SAGE Publishing
series Clinical Medicine Insights: Oncology
issn 1179-5549
publishDate 2008-01-01
description Atypical fibroxanthoma (AFX) is a nodular dermal ulcerative lesion with a favorable prognosis. AFX most commonly occurs on sun-exposed skin in elderly individuals. AFX is characterized by its association with ultraviolet radiation, not only from a clinical aspect, but also from a molecular aspect. Making a diagnosis of AFX is challenging, and it is important to differentiate it from squamous cell carcinoma and malignant melanoma. Histological features and combined immunohistochemical markers are necessary for a definitive diagnosis (i.e., an absence of immunostaining for cytokeratins, S100 and HMB45 in AFX is helpful for excluding both squamous cell carcinoma and malignant melanoma). AFX, as well as MFH (malignant fibrous histiocytoma), is a fibrohistiocytic lesion with myofibroblastic differentiation. AFX is considered to be a different lesion from MFH. AFX and MFH might share the same pathway which determines their morphology. However, they may have different pathways in development which determine their biological behavior.
url https://doi.org/10.4137/CMO.S506
work_keys_str_mv AT akiosakamoto atypicalfibroxanthoma
_version_ 1724499984243490816